Net Asset Value

RNS Number : 4243W

Port Erin Biopharma Investments Ltd

25 January 2013

Port Erin Biopharma Investments Limited ("the Company")

Net Asset Value calculation to 31^st December 2012

Jim Mellon, Chairman, commented: -

"The Net Asset Value ("NAV") calculation for the Company as at closing on 31 December 2012 was 9.50 pence per share, including un-invested cash of £101,241. The portfolio is valued under IFRS at bid price. This quarter's NAV represents a small decrease from the previous valuation of 9.63 pence per share, which included un-invested cash of £329,708. The revenue reserve has increased substantially following the deduction of listing expenses from the share premium account and still represents a return of over 16.0% on investments after operating costs. Indeed, if the NAV valuation were to be published today, the NAV per share would approach 10.4 pence."

		Unaudited 15 September 2011 to 31 December 2012 £
Fixed Assets
	Investments	3,031,135
Current Assets
	Debtors: amounts owing	9,035
	Un-invested cash	101,241
Current Liabilities
	Creditors: amounts due	(7,292)
		3,134,119
Capital and Reserves
	Share Capital	33
	Share Premium	2,699,011
	Capital reserve - realised	0
	Capital reserve - unrealised	0
	Revenue reserve	435,075
		3,134,119

Shares in Issue		33,000,000
Net Asset Value per share		9.50 pence

--- ENDS ---

Portfolio Details

Investments Schedule at 31st December 2012	Valuation £	Portfolio %

Summit Corporation plc	£269,166.87	8.88%
Cytox Limited	£200,000.00	6.60%
Gilead Sciences Inc.	£195,452.13	6.45%
Synergy Pharmaceuticals Inc.	£182,814.82	6.03%
Plethora Solutions Holdings plc	£180,000.00	5.94%
Celgene Inc.	£141,125.68	4.66%
Astellas Pharma Inc.	£140,762.00	4.64%
Arrowhead Resources	£135,419.97	4.47%
TrovaGene Inc.	£127,845.13	4.22%
Abbott Laboratories	£117,762.25	3.89%
Pfizer Inc.	£114,835.48	3.79%
	£1,805,184.33	59.55%

Aggregate value of remaining holdings below 3% of total portfolio	£1,225,950.25	40.45%

TOTAL INVESTMENTS	£3,031,134.58	100.00%